KN
Kane Biotech Inc.
KNBIF · OTC
$0.02 +0.00% (+$0.00)
1M +17.30%
Market Cap $6.23M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 161.80x
PEG N/A
P/E N/A
Growth
0 /100
Declining Rev. growth 45.69%
Book val. growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 8,162.01%
Gross margin 505.99%
FCF margin 6,257.16%
Quality
0 /100
Poor Asset turnover 0.02x
ROIC 312.41%
ROA 121.24%
Debt
6 /100
High Int. coverage -17.23x
Current ratio 0.61x
Debt/Assets N/A
Stability
32 /100
Unstable EPS volatility 22.98%
Beta 0.31x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o KNBIF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert Huizinga
Employees
20
Headquarters
Winnipeg
Prihajajoči dogodki
26 NOV.
Earnings
Upcoming earnings report